Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Any idea what all those big trades are from Friday? Normally lucky to see a couple of trades.
Just going to put here what I am hearing, take it with a pinch of salt. The in vivo data is looking very good ( this was more or less confirmed in the recent presentation) and we are likely to sign 2 types of deals with interested parties. Now the interesting part is that we have partnerships with pharma companies that are likely to sign deals if the data is good enough, however a number of companies that do not have partnerships with us have also approached the company and want to see the data with a view to signing a deal. The deals will be either a technology platform partnership or we will license the platform.
The incoming CEO was part of GW Pharma that was taken over for $7.2B. He knows how to do great deals and will either sign a licensing deal for XF-73 or sell the rights to it. To buy the rights they will have to pay over $200M for them as a minimum, which is over £2 a share. Just shows how ridiculously cheap Dest is at present.
Taken a starter position here. Need to do more research before adding further. If anyone on here could assist with the following it will be much appreciated.
The warrants at $11.50, what do they equate to in pounds?
The FDA submission in 2023- when is that likely to happen and how long for FDA to respond?
Thanks
The following in the RNS caught my eye. '' I am really looking forward to September, when I can take over the reins from Debra, who has made a significant impact in a short space of time."
We know Debra was leading the discussions for XF-73, so could we have entered exclusive discussions with a potential partner, otherwise why mention significant impact. Just my thoughts.
It is obvious the data is looking very good, was hinted at in the presentation. A number of parties are waiting to see the data before committing to deals. As per the presentation Iain said the in vivo data will be available any day now. At this price it has to be a strong buy.
The reason the CEO was pushed was due to the poor deal for M3, only $1m upfront and a placing at a crappy price of 35p. The company received a lot of stick from shareholders for that deal and ultimately the CEO paid the price.
The reason for the drop is that most probably were expecting the discussions to be at a more advanced stage than they are. What most are missing is that some very big players in the pharma space are interested in XF-73 and the company wants one of the big boys as partner with some very large numbers in the licensing deal. They will not rush this deal and I am more than happy to wait for the right deal and partner. Would love for the partner to be GSK.
You missed the important bit in the RNS. In discussions with GLOBAL partners, from what I am hearing 2 Hugh pharma are interested in XF-73. The company won't be rushing this deal and expect this deal to blow away the licensing deal for M3.
He will not get the £175K bonus as he had to spend £75K in purchasing shares before March 2023. He spent £55K and only needed to spend another £20K to claim the £175K bonus. So the question is why didn't he.
Decent volume again so far today. Antimicrobial resistance news in the telegraph might be helping, see below.
https://t.co/VBw13rIWRY
As some are wondering what the reason is for the rise in share price. Yesterday a delayed trade of about 2.4 Million shares appeared after hours. My guess is that Obotritia Capital KGaA has sold it's last lot and is now fully out. They were the seller over the last few months that had caused the drop. I was waiting for them to be out before I added more and it looks like others have done the same, hence the rise.
I can see the share price rising steadily over the next month a positions are taken in anticipation of an update on the in vivo data as promised by Iain in the recent presentation. Iain hinted that the data was looking very good, so I am expecting a very good update. This data will be sufficient to then begin discussions and hopefully sign a licensing deal.
Wanted another 100K shares this morning but was NT. Had to buy in smaller amounts to get filled. Have added substantially over the last few days. Even after averaging down, currently underwater here but have brought my average down. I am one of the very few that still believes Rene will come good.
Expecting update on in vivo data in about 6 weeks and then enter licensing deal discussions with partner. Need that first licensing deal and then sentiment will change.